Polymyxin b hemoperfusion in clinical practice: The picture from an unbound collaborative registry

Blood Purification

Volumn 37, Issue SUPPL. 1, 2014, Pages 22-25

  Antonelli, Massimo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

EUPHAS2 trial; Polymyxin B; Toraymyxin

Indexed keywords

ENDOTOXIN; POLYMYXIN B; TORAYMYXIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL PRACTICE; DISEASE SEVERITY; FEMALE; HEMOPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONABDOMINAL SEPSIS; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TREATMENT DURATION; CLINICAL FEATURE; DATA COLLECTION METHOD; DISEASE REGISTRY; DRUG DELIVERY DEVICE; HOSPITAL; MEDICATION COMPLIANCE; MORTALITY; PATIENT COMPLIANCE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; FEMALE; HEMOPERFUSION; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; POLYMYXIN B; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SEPSIS;

EID: 84893235787     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000356835     Document Type: Article

References (14)

1. Cruz DN, Antonelli M, Fumagalli R, et al: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445-2452.
2. Vincent JL: Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA 2009; 302: 1968, author reply 1969-1970.
3. Abe S, Azuma A, Mukae H, et al: Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis. Intern Med 2012; 51: 1487-1491.
4. Kono M, Suda T, Enomoto N, et al: Evaluation of different perfusion durations in direct hemoperfusion with polymyxin B-immobilized fiber column therapy for acute exacerbation of interstitial pneumonias. Blood Purif 2011; 32: 75-81.
5. Romaschin AD, Walker PM: Endotoxin activity in whole blood by neutrophil chemiluminescence- A novel analytical paradigm. Clin Chem 2000; 46: 1504-1506.
6. Romaschin AD, Klein DJ, Marshall JC: Bench-to-bedside review: clinical experience with the endotoxin activity assay. Crit Care 2012; 16: 248.
7. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60.
8. Novelli G, Ferretti G, Ruberto F, Morabito V, Pugliese F: Early management of endotoxemia using the endotoxin activity assay and polymyxin B-based hemoperfusion. Contrib Nephrol 2010; 167: 91-101.
9. Quenot JP, Binquet C, Kara F, et al: The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study. Crit Care 2013; 17:R65.
10. Sakr Y, Elia C, Mascia L, Barberis B, et al: Epidemiology and outcome of sepsis syndromes in Italian ICUs: a regional multicenter observational Cohort. Minerva Anestesiol 2013; 79: 993-1002.
11. Starr RG, Lader AS, Phillips GC, Stroman CE, Abel FL: Direct action of endotoxin on cardiac muscle. Shock 1995; 3: 380-384.
12. Stetson CA: Vascular effects of endotoxins. Bull NY Acad Med 1961; 37: 486-492.
13. Cantaluppi V, Assenzio B, Pasero D, et al: Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med 2008; 34: 1638-1645.
14. Zagli G, Bonizzoli M, Spina R, et al: Effects of hemoperfusion with an immobilized Polymyxin- B fiber column on cytokine plasma levels in patients with abdominal sepsis. Minerva Anestesiol 2010; 76: 405-412.